OncoResponse to Present Phase 1 Results of OR502 Study at SITC 2024

HOUSTON, Nov. 4, 2024 /PRNewswire/ -- OncoResponse, a biotech firm at the forefront of cancer immunotherapy, has announced the presentation of Phase 1 results from its clinical study of OR502. OR502 is a cutting-edge, humanized antibody targeting the leukocyte immunoglobulin-like receptor B2 (LILRB2), which is critical in counteracting immune suppression mediated by LILRB2. The findings from this study will be shared as a late-breaker poster during the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) scheduled in Houston, Texas, from November 8 to 10, 2024.

The presentation details are as follows:
- Title (Late-Breaking Abstract): Phase 1 results of OR502, an antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in subjects with advanced cancers
- Abstract Number: 1464
- Date and Venue: Saturday, November 9, George R. Brown Convention Center

Additionally, another crucial presentation will be:
- Title: Adaptive design elements in a Ph 1-2 study of OR502, a novel antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in response to evolving Ph 1 data and changing regulatory environment
- Abstract Number: 680
- Date and Venue: Saturday, November 9, George R. Brown Convention Center

These poster presentations will later be accessible on the Publications page of OncoResponse's website after the sessions conclude.

About OncoResponse:
OncoResponse is a clinical-stage company focusing on immuno-oncology, developing immunotherapies against cancer using insights from the immune systems of Elite Cancer Responders. Through a strategic partnership with MD Anderson Cancer Center, OncoResponse leverages a unique B-cell discovery platform to find and develop innovative antibodies that target immune cells within the tumor microenvironment. The leading clinical candidate, OR502, is an advanced anti-LILRB2 antibody designed to restore both innate and adaptive immune responses from LILRB2-mediated immune suppression. OR502 entered clinical trials in 2023 with support from the Cancer Prevention Research Institute of Texas (CPRIT) under grant DP230076.